Northwestern University

Other

Immtech International Inc.

Bio Science International, Inc.

Byron E Anderson

Michael A Baumann

Lawrence A Potempa

Jonathan P Fryer

John J Kresl

Lyman E Davis

Mark L Pankow

Pamela Bean

Brandt J Fine

Marilyn R Brown

Samar Makhlouf

Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids. Also disclosed are methods for identifying small D-peptides comprising aromatic D-amino acids that bind to proteins of interest.

Peptides comprising aromatic D-amino acids and methods of use

The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. The invention further provides a method of prolonging the survival of tissue transplanted into a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. The invention also provides a method of treating an inflammatory response in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan. Finally, the invention provides a pharmaceutical composition comprising a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan-tryptophan in a pharmaceutically-acceptable vehicle.

Method and material for inhibiting complement

The invention provides a method of inhibiting complement in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. The invention further provides a method of prolonging the survival of tissue transplanted into a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. The invention also provides a method of treating an inflammatory response in a mammal comprising administering to the mammal an effective amount of a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan. Finally, the invention provides a pharmaceutical composition comprising a carrier having coupled thereto a plurality of dipeptides selected from the group consisting of tryptophan-tyrosine, tyrosine-tryptophan and tryptophan--tryptophan in a pharmaceutically-acceptable vehicle.

The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence:

Synthetic peptide and its uses

The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid. The binding material comprises plural binding peptides, the peptides being characterized in that a plurality of them selectively binds immune complexes and aggregated immunoglobulins in the presence of monomeric immunoglobulin.

The invention provides an antibody which reacts selectively with a transferrin homolog found in alcoholics but not in non-alcoholics. The invention also provides methods of making the antibody and hybridomas producing the antibody. Finally, the invention provides an immunoassay which utilizes the antibody to detect or quantitate the alcoholic transferrin homolog and a kit for an immunoassay which comprises a container of the antibody.

Immunoassay for identifying alcoholics and monitoring alcohol consumption

A method of binding aggregated immunoglobulin or immune complexes comprising contacting them with modified forms of C-reactive protein. The method may be employed for diagnostic and therapeutic purposes and to deplete fluids of aggregated immunoglobulin or immune complexes. Further, a method of reducing the levels of immune complexes in a mammal comprising administering modified-CRP to the mammal, and a method of binding immunoglobulins comprising contacting them with modified C-reactive protein. Also, a method of binding aggregated immunoglobulin or immune complexes comprising contacting them with antibody to neo-CRP, and a method of modifying C-reactive protein. Finally, a test kit for detecting or quantitating immune complexes and a device for removing aggregated immunoglobulin or immune complexes from fluids are disclosed.

Binding of immune complexes by modified forms of C-reactive protein

An immunoassay for a protein that is non-enzymatically glycosylated on the alpha amino group of its N-terminal amino acid, the immunoassay comprising: providing a sample containing the glycosylated protein; reacting the glycosylated protein with a reducing agent so that the sugar residue on the N-terminal amino acid is reduced; contacting the reduced glycosylated protein with an antibody directed to Glc-ol-X which is prepared by immunizing an animal with an immunogen of the formula (Glc-ol-X-L).sub.n -carrier; and detecting or quantitating the reduced glycosylated protein bound to the antibody. In the formula (Glc-ol-X-L).sub.n -carrier: X is the N-terminal amino acid of the glycosylated protein, except that X cannot be lysine; L is a bond or a linker group; Glc-ol is the reduced form of the sugar attached to X on the glycosylated protein, and Glc-ol is attached to the alpha amino group of X; the carrier is an immunogenic compound other than the glycosylated protein; and n is from 1 to the number of available coupling sites on the carrier. Also, the antibody, the immunogen, and methods of making them. Finally, a kit for quantitating a protein glycosylated on its N-terminal amino acid.

Immunoassay of glycosylated proteins employing antibody directed to

The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ('mCRP'). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.

Methods of imaging cancer cells using modified C-reactive protein

The invention provides a method of screening for gastrointestinal cancer in a mammal comprising: (a) contacting a body fluid taken from the mammal with N3; (b) measuring the amount of antibody to N3 in the body fluid; and (c) determining if the amount of antibody measured in step (b) is higher than the amount of antibody to N3 normally present in the same type of body fluid taken from mammals of the same species that do not have cancer. The invention also provides kits for screening for gastrointestinal cancer in a mammal by measuring the mammal's level of antibodies to N3.

Method of detecting cancer

The invention provides a fragment of Clq which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the Clq fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid. The binding material comprises plural binding peptides, the peptides being characterized in that a plurality of them selectively binds immune complexes and aggregated immunoglobulins in the presence of monomeric immunoglobulin.

Synthetic C1q peptide fragments

Methods of treating cancer using modified C-reactive protein

An information display system and method for displaying information on multiple information display means. The information display system is generally comprised of a system controller, one or more direct controller, multiple information display units and one or more display lines, which facilitate the transmission of operating power and information to the information display units. The system controller combines each unit of source information with its own address code, thereby forming an addressed information unit. The system controller transmits the addressed information unit to a direct controller designated by said information unit's address code. The direct controller utilizes the address code to then store the information unit relative to other information units such that when it is later serially transmitted with the other information units to be displayed on the same display line, each information unit ends up at the information display unit designated by its address code and is converted to a visual display.

Growing community of inventors

Morton Grove, IL, United States of America

Byron E Anderson